Filters
Sort results
Reset
Apply
Cat No. | Products Name | Name | Previous Name | Target | Format | Options | Order | quote |
|---|---|---|---|---|---|---|---|---|
Pre-Made Acapatamab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody |
Acapatamab |
NA |
FOLH1/GCPII,CD3E |
Bispecific scFv |
||||
Pre-Made Alnuctamab biosimilar, Bispecific mAb with Domain Crossover, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody |
Alnuctamab |
NA |
TNFRSF17,CD3E |
Bispecific mAb with Domain Crossover |
||||
Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody |
Blinatumomab |
NA |
CD19,CD3E |
Bispecific T-Cell Engager |
||||
Pre-Made Cibisatamab biosimilar, Bispecific mAb with Domain Crossover: Anti-CEACAM5;CD3E therapeutic antibody |
Cibisatamab |
NA |
CEACAM5,CD3E |
Bispecific mAb with Domain Crossover |
||||
Pre-Made Dafsolimab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
Dafsolimab |
NA |
CD3E |
Whole mAb |
||||
Pre-Made Duvortuxizumab biosimilar, Bispecific scFv with Crossover, Anti-CD19;CD3E antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody |
Duvortuxizumab |
NA |
CD19,CD3E |
Bispecific scFv with Crossover |
||||
Pre-Made Eluvixtamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody |
Eluvixtamab |
NA |
CD33,CD3E |
Bispecific scFv |
||||
Pre-Made Emerfetamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody |
Emerfetamab |
NA |
CD33,CD3E |
Bispecific scFv |
||||
Pre-Made Envafolimab biosimilar, Single Domain Variable Fragment;H, Anti-CD274/PD-L1 Antibody: Anti-B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1 therapeutic antibody |
Epcoritamab |
NA |
CD3E,MS4A1 |
Bispecific mAb |
||||
Pre-Made Etevritamab biosimilar, Bispecific scFv, Anti-EGFR;CD3E Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;T3E/TCRE/IMD18 therapeutic antibody |
Etevritamab |
NA |
EGFR,CD3E |
Bispecific scFv |
||||
Pre-Made Flotetuzumab biosimilar, Bispecific scFv with Crossover, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody |
Flotetuzumab |
NA |
IL3RA,CD3E |
Bispecific scFv with Crossover |
||||
Pre-Made Foralumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
Foralumab |
NA |
CD3E |
Whole mAb |
||||
Pre-Made Glofitamab biosimilar, Bispecific mAb with Domain Crossover, Anti-CD3E;MS4A1/CD20 antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7therapeutic antibody |
Glofitamab |
NA |
CD3E,MS4A1 |
Bispecific mAb with Domain Crossover |
||||
Pre-Made Mosunetuzumab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
Mosunetuzumab |
NA |
CD3E,MS4A1 |
Bispecific mAb |
||||
Pre-Made Muromonab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
Muromonab |
NA |
CD3E |
Whole mAb |
||||
Pre-Made Nivatrotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-GD2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
Nivatrotamab |
NA |
GD2,CD3E |
Bispecific Mixed mAb and scFv |
||||
Pre-Made Obrindatamab biosimilar, Bispecific scFv with Domain Crossover, Anti-CD276;CD3E Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 therapeutic antibody |
Obrindatamab |
NA |
CD276,CD3E |
Bispecific scFv with Domain Crossover |
||||
Pre-Made Odronextamab biosimilar, Bispecific mAb, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody |
Odronextamab |
NA |
MS4A1,CD3E |
Bispecific mAb |
||||
Pre-Made Otelixizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
Otelixizumab |
NA |
CD3E |
Whole mAb |
||||
Pre-Made Pacanalotamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody |
Pacanalotamab |
NA |
TNFRSF17,CD3E |
Bispecific scFv |
